FDA Approves Apretude: First Injectable PrEP for HIV Prevention

Key Takeaways

• Main news: The U.S. Food and Drug Administration (FDA) granted cabotegravir (Apretude) approval as the first long-acting injectable pre-exposure prophylaxis (PrEP) option for reducing the risk of HIV-1 infection.
• Clinical impact: Clinical trials demonstrated superior efficacy of Apretude injections compared to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in preventing HIV-1 infection.
• Market implications: This Infectious diseases approval introduces a new modality in the competitive PrEP market, potentially improving adherence and expanding prevention options for at-risk populations.
• Next steps: Pricing and reimbursement strategies will influence market penetration and access.

The HIV prevention landscape saw a significant shift with the cabotegravir (Apretude) approval by the U.S. Food and Drug Administration (FDA). This FDA Apretude approval marks the first long-acting injectable option for pre-exposure prophylaxis (PrEP), offering a new approach to reduce the risk of HIV-1 infection in at-risk individuals. The FDA's decision provides an alternative to daily oral PrEP regimens, addressing adherence challenges and expanding prevention options.

Drug Overview

Apretude (cabotegravir) is an integrase strand transfer inhibitor (INSTI). Its mechanism of action involves inhibiting HIV integrase, which prevents viral DNA from integrating into the host cells. The FDA approved it for reducing the risk of HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV-1.

Clinical Insights

The FDA approval was supported by data from Phase III trials, including HPTN 083 and HPTN 084. [Source: U.S. Food and Drug Administration] These trials demonstrated that cabotegravir injections resulted in statistically significant reductions in new HIV-1 infections compared to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF). Common adverse events included injection site reactions such as pain, swelling, and nodules. Systemic side effects were generally mild and similar to those observed with oral PrEP, including headache and fatigue.

Regulatory Context

The approval of Apretude by the FDA followed standard new drug application (NDA) pathways, including preclinical studies and phased clinical trials. Given the public health importance, the review process may have been expedited through priority review and breakthrough therapy designations.

Market Impact

Apretude enters a competitive U.S. PrEP market where oral regimens such as emtricitabine/tenofovir disoproxil fumarate and emtricitabine/tenofovir alafenamide are already established. The injectable format is positioned to appeal to individuals who face challenges with daily oral adherence or prefer less frequent dosing. Why it matters: Apretude is the first long-acting injectable PrEP option, potentially improving adherence and expanding prevention options for at-risk populations. Its long-acting injectable formulation, administered every two months, offers a distinct advantage compared with daily oral dosing, offering improved adherence convenience and superior efficacy demonstrated in clinical trials.

Future Outlook

What to watch next: Further label expansions and studies exploring cabotegravir in combination with other prevention strategies are anticipated. Analysts predict that increased adoption could shift market dynamics and stimulate further innovation.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-20.

Related profiles

• cabotegravir

Related coverage

• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
• Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials